Compare BHF & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHF | TLX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | BHF | TLX |
|---|---|---|
| Price | $64.16 | $7.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $58.88 | $21.00 |
| AVG Volume (30 Days) | ★ 807.9K | 200.6K |
| Earning Date | 02-10-2026 | 01-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 14.74 | 0.04 |
| Revenue | ★ $7,830,000,000.00 | $664,225,558.00 |
| Revenue This Year | $40.59 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | ★ $4.35 | $240.62 |
| Revenue Growth | 48.75 | ★ 55.35 |
| 52 Week Low | $42.07 | $7.31 |
| 52 Week High | $66.33 | $30.36 |
| Indicator | BHF | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 43.28 |
| Support Level | $64.02 | $7.42 |
| Resistance Level | $65.36 | $7.71 |
| Average True Range (ATR) | 0.45 | 0.15 |
| MACD | -0.23 | 0.07 |
| Stochastic Oscillator | 21.79 | 70.31 |
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.